Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.

Authors

null

Kimberly Mayumi Komatsubara

Columbia University Medical Center, New York, NY

Kimberly Mayumi Komatsubara , Robyn Denise Gartrell , Claire-Audrey Bayan , Jaya Sarin Pradhan , Syed Shabee Hasan , Thomas D Hart , Margaret Borgardus , Yan Lu , Douglas Kanter Marks , Jessica Yang , Adriana Lopez , Codruta Chiuzan , Basil Horst , Bret Taback , Larisa J. Geskin , Brian P. Marr , Gary K. Schwartz , Yvonne M. Saenger , Richard D. Carvajal

Organizations

Columbia University Medical Center, New York, NY, Columbia University College of Physicians and Surgeons, New York, NY, Columbia University, New York, NY, Department of Pathology and Laboratory Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada

Research Funding

NIH

Background: Uveal melanoma (UM) is a rare subset of melanoma that is resistant to immune checkpoint blockade. High density of macrophages (Mϕ) and TILs is associated with poor prognosis in primary UM but little is known about the tumor microenvironment (TME) in metastatic UM (MUM). Here we performed quantitative spatial analysis using multiplex immunohistochemistry (mIHC) to characterize the TME in MUM, compare the TME of MUM to metastatic cutaneous melanoma (MCM), and identify potential mechanisms of MUM resistance to immunotherapy. Methods: We identified pts with untreated metastatic melanoma with clinical follow-up and available pre-treatment tissue who consented to an IRB-approved protocol. 5µm slides were stained using Opal mIHC for DAPI, CD3, CD8, CD68, HLA-DR, Ki67, and SOX10. Tumor areas were pre-selected by a dermatopathologist, visualized using Vectra and analyzed for density and spatial localization using inForm software. Results: 6 MUM and 8 MCM cases were evaluable at the time of this analysis. CD3+ and CD8+ T-cell density is similar between MUM and MCM, however, there is a trend towards a higher density of proliferating cytotoxic T lymphocytes (CTL) (CD8+Ki67+) in MCM (p = 0.05). Interestingly, CD68+ Mϕ density is lower in MUM compared to MCM (p = 0.03). Both CD68+HLA-DR+ Mϕ (activated) and CD68+HLA-DR- Mϕ (inactivated) density is lower in MUM. Using nearest neighbor spatial analysis, CD8+ CTLs are significantly farther from activated Mϕ (CD68+HLA-DR+) (p = 0.01), but not from inactivated Mϕ (CD68+HLA-DR-) in MUM compared to MCM. Conclusions: Unlike primary UM, our sample of untreated MUM is not characterized by a high Mϕ density. Fewer Mϕ are present in untreated MUM compared to MCM and activated Mϕ are located farther from CTLs in UM. Density of CTLs is similar in MUM and MCM, although proliferating CTL are more numerous in MCM. These preliminary results suggest that Mϕ may play a less prominent role in innate resistance to immunotherapy in MUM. Gene expression analysis and further classification of Mϕ type is ongoing. Additional cases are ongoing analysis and will be reported.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Citation

J Clin Oncol 36, 2018 (suppl; abstr 9570)

DOI

10.1200/JCO.2018.36.15_suppl.9570

Abstract #

9570

Poster Bd #

397

Abstract Disclosures

Similar Abstracts

First Author: Bhavika Patel

First Author: Jian Guan

First Author: Katherine Emilie Rhoades Smith